Orexo

Orexo Liabilities

The The Liabilities of Orexo (ORX.ST) as of Nov 1, 2026 is 812.20 M SEK. In the previous year, The Liabilities was 721.10 M SEK — a change of 12.63% (higher).

Liabilities

812.20 MSEK

YoY

12.63%

Last updated:

In 2025, Orexo's total liabilities amounted to 812.20 M SEK, a 12.63% difference from the 721.10 M SEK total liabilities in the previous year.

The Orexo Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
810.60 M SEK
Jan 1, 2019
794.70 M SEK
Jan 1, 2020
674.40 M SEK
Jan 1, 2021
924.10 M SEK
Jan 1, 2022
915.10 M SEK
Jan 1, 2023
727.70 M SEK
Jan 1, 2024
721.10 M SEK
Jan 1, 2025
812.20 M SEK
The Orexo Liabilities history
YEARLiabilitiesYoY
812.20 MSEK+12.63%
721.10 MSEK-0.91%
727.70 MSEK-20.48%
915.10 MSEK-0.97%
924.10 MSEK+37.03%
674.40 MSEK-15.14%
794.70 MSEK-1.96%
810.60 MSEK+20.12%
674.80 MSEK-4.76%
708.50 MSEK-5.51%
749.85 MSEK-2.73%
770.86 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orexo Stock analysis

What does Orexo do? Orexo AB is a Swedish pharmaceutical company that was founded in 1995 and is headquartered in Uppsala. The company focuses on the development of medications for the treatment of pain and addiction disorders. Business model: Orexo's business model is based on the development of innovative medications and their marketing in the global market. The company specializes in the development of medications based on opioid technology. Divisions: Orexo operates in two main business areas: Pharmaceuticals and digital therapeutics. Pharmaceuticals: In the pharmaceutical division, Orexo is primarily involved in the development of medications used in the treatment of pain and addiction disorders. Some of the best-known medications include: - Zubsolv: a medication for the treatment of opioid addiction - Abstral: a fast-acting pain medication for cancer patients - Edluar: a sleep medication for the treatment of sleep disorders Orexo's pharmaceuticals are distributed in over 60 countries worldwide and have already helped many patients alleviate their symptoms. Digital therapeutics: Orexo has expanded its business model and offers digital therapeutics - apps that contribute to improving the success of pain and addiction disorder treatment. One example is the app "Orexo Digital," which helps patients better monitor their medication and document the progress of their treatment. The app is free and can be downloaded by patients who have been prescribed medications from Orexo. History: Orexo was founded in 1995 by a team of researchers from Uppsala University. The company initially focused on the development of medications for the treatment of inflammatory diseases and allergies. In 2003, the company decided to concentrate on the development of medications in pain and addiction treatment. The first products in this area were the pain medication Abstral and the substitution medication Zubsolv. In the following years, the company grew rapidly and opened additional locations in the United States, United Kingdom, and France. Orexo works closely with key players in the healthcare sector to ensure that its medications are accessible to patients worldwide. Products: Abstral: a medication for the treatment of acute and chronic severe pain. It is taken sublingually and acts quickly. Zubsolv: a medication for the treatment of opioid addiction. It contains the active ingredients buprenorphine and naloxone and can alleviate withdrawal symptoms in opioid addiction. Edluar: a sleep medication for the treatment of sleep disorders. It contains the active ingredient zolpidem and is taken sublingually. Orexo Digital: an app to support patients in the treatment of pain and addiction disorders. It enables the monitoring of treatment progress and provides helpful advice for improving treatment success. Conclusion: Orexo is an innovative pharmaceutical company specializing in the development of medications for the treatment of pain and addiction disorders. The company has made a name for itself with its unique opioid technology and offers successful products such as Abstral and Zubsolv. With its expansion into the field of digital therapeutics, Orexo also demonstrates that it remains at the forefront of technology and innovation. Orexo is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Orexo's Liabilities

Orexo's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Orexo's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Orexo's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Orexo's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Orexo’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Orexo stock

The Liabilities of Orexo is 812.20 M SEK in 2025.

The Liabilities of Orexo changed from 721.10 M SEK to 812.20 M SEK, representing a 12.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Orexo since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Orexo historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Orexo

All Key Metrics — Orexo